Pharmacokinetics of diaspirin cross‐linked haemoglobin in a rat model of hepatic cirrhosis *

R. Palaparthy,H. Kastrissios,A. Gulati

DOI: https://doi.org/10.1211/0022357011775370

2001-02-01

Abstract:The aim of the study was to evaluate the effect of cirrhosis on the disposition of the haemoglobin‐based oxygen carrier, diaspirin cross‐linked haemoglobin (DCLHb). Cirrhosis was induced in male Sprague‐Dawley rats (200–250 g) by inhalational exposure to carbon tetrachloride (CCl4), over a period of 6 weeks. Pharmacokinetic evaluation was performed after a single intravenous bolus administration of DCLHb (400 mg kg−1). Serum biochemistry, including aspartate transaminase, alkaline phosphatase, bile acids, serum albumin, and serum creatinine, were measured in CCl4‐treated (n = 6) and age‐matched control (n = 6) rats. After 6 weeks, the jugular vein and carotid artery were cannulated for bolus DCLHb administration (400 mg kg−1) and blood sampling, respectively, in both groups of rats. Cirrhosis produced significant (P < 0.05) elevations in alkaline phosphatase (497.4 ± 84.8 U L−1 vs 241.2 ± 5.1 U L−1), aspartate transaminase (920.5 ± 190.9 U L−1 vs 238.2 ± 118.1 U L−1) and bile acids (333.8 ± 77.3 mg dL−1 vs 43.8 ± 4.2 mg dL−1) compared with the control group. No significant renal dysfunction was observed as a result of CCl4 exposure. Plasma DCLHb concentrations declined approximately log‐linearly. Systemic clearance of DCLHb was estimated to be 2.2 ± 0.7 mL h−1 in the treatment group and was slightly, but not significantly, less in the control group (3.6 ± 1.7 mL h−1). There was also a trend toward a longer elimination half‐life in the treatment group (4.7 ± 2.2 h) compared with the control group (3.8 ± 0.8 h), although this difference was not statistically significant. Cirrhosis does not significantly alter the disposition of DCLHb perhaps due to increased extra‐hepatic metabolism by the reticulo‐endothelial system.